Clinical treatment controversies and progress in liver cirrhosis: an evidence-based medicine perspective from managing portal hypertension to preventing complications
10.3760/cma.j.cn501113-20250319-00101
- VernacularTitle:肝硬化临床治疗争议与进展：从门静脉高压管理到并发症防治的循证医学视角
- Author:
Yufei YANG
1
;
Junjun WANG
1
;
Guangwen CHEN
1
;
Qichao GE
1
;
Lungen LU
1
Author Information
1. 上海交通大学医学院附属第一人民医院消化科，上海 200080
- Publication Type:Journal Article
- Keywords:
Cirrhosis;
Clinical treatment controversies;
Evidence-based medicine;
Precision medicine
- From:
Chinese Journal of Hepatology
2025;33(8):734-737
- CountryChina
- Language:Chinese
-
Abstract:
Liver cirrhosis as the terminal stage of chronic liver disease has seen many new insights and advances in its treatment strategies and perspectives in recent years. However, there are still many controversies about cirrhotic portal hypertension management, prevention, therapy, and complications. This article summarizes the main key controversial points in the current treatment of liver cirrhosis from an evidence-based medicine perspective, including the use of non-selective β-blockers during decompensated stages, exploration of precise strategies for albumin, re-evaluation of the risks of statins, weighing the pros and cons of proton pump inhibitors, new understandings of anticoagulation therapy, breakthroughs in targeting gut microbiota, and nutritional support management. In addition, it combines the latest research data and guideline recommendations to explore future development directions so as to provide clinical practice reference.
